Emergent Biosolutions Inc. revenue
Emergent Biosolutions Inc.'s revenue was $743m in fiscal 2025, down 28.8% on the year before. Since fiscal 2009 ($235m) it has grown at a compound 7.5% a year. Over the last twelve months it was $649m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 235 | 286 | 273 | 282 | 313 | 450 | 523 | 489 | 561 | 782 | 1,106 | 1,577 | 1,774 | 1,118 | 1,049 | 1,044 | 743 | 649 |
| Growth on the year before | — | +21.9% | −4.5% | +3.1% | +10.9% | +43.9% | +16.1% | −6.5% | +14.8% | +39.5% | +41.4% | +42.6% | +12.4% | −37.0% | −6.1% | −0.5% | −28.8% | — |
| Gross profit | — | — | — | — | — | — | — | 363 | 373 | 460 | 673 | 925 | 891 | 383 | 318 | 362 | 417 | 314 |
| Gross margin | — | — | — | — | — | — | — | 74.2% | 66.5% | 58.8% | 60.8% | 58.7% | 50.3% | 34.3% | 30.3% | 34.7% | 56.1% | 48.4% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| MCM Products | $457M | ▼ 10.4% |
| Commercial Products | $226M | ▼ 43.3% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Line of business | Revenue | YoY |
|---|---|---|
| Product and Service | $705M | ▼ 30.4% |
| Medical Countermeasures MCM Product | $457M | ▼ 10.4% |
| Commercial Product | $226M | ▼ 43.3% |
| All Other Revenue | $60.1M | ▼ 55.4% |
| Contracts and Grants | $37.7M | ▲ 25.7% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $531M | 71.5% | ▼ 35.4% |
| Other Geographical Area | $137M | 18.4% | ▲ 69.7% |
| Canada | $75M | 10.1% | ▼ 46.6% |
From Emergent Biosolutions Inc.'s 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Emergent Biosolutions Inc. | $649m | -17.7% | -16.2% |
| Travere Therapeutics, Inc. | $651m | 49.4% | 71.3% |
| Alvotech | $586m | 19.7% | — |
| Amphastar Pharmaceuticals, Inc. | $730m | 1.0% | 10.5% |
| Pacira Biosciences, Inc. | $746m | 5.7% | 3.7% |
| Corcept Therapeutics Inc | $831m | 16.0% | 24.7% |
Compare with peers
- Travere Therapeutics, Inc. revenue
- Alvotech revenue
- Amphastar Pharmaceuticals, Inc. revenue
- Pacira Biosciences, Inc. revenue
- Corcept Therapeutics Inc revenue
Head to head: EBS vs TVTXALVO vs EBSAMPH vs EBS
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies